Prosecution Insights
Last updated: November 04, 2026
Application No. 18/648,073

ANTI-CCR8 ANTIBODIES, CONJUGATES, AND USES THEREOF

Non-Final OA §112
Filed
Apr 26, 2024
Priority
Apr 28, 2023 — provisional 63/498,977
Examiner
NICKOL, GARY B
Art Unit
1643
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Abilita Therapeutics Inc.
OA Round
1 (Non-Final)
47%
Grant Probability
Moderate
1-2
OA Rounds
1y 3m
Est. Remaining
77%
With Interview

Examiner Intelligence

Grants 47% of resolved cases
47%
Career Allowance Rate
35 granted / 74 resolved
-12.7% vs TC avg
Strong +30% interview lift
Without
With
+30.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 9m
Avg Prosecution
55 currently pending
Career history
124
Total Applications
across all art units

Statute-Specific Performance

§101
3.7%
-36.3% vs TC avg
§103
22.4%
-17.6% vs TC avg
§102
22.2%
-17.8% vs TC avg
§112
37.7%
-2.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 74 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 129-148 are pending and under consideration. Specification The disclosure is objected to because it contains an embedded hyperlink and/or other form of browser-executable code. See [0164]. Applicant is required to delete the embedded hyperlink and/or other form of browser-executable code; references to websites should be limited to the top-level domain name without any prefix such as http:// or other browser-executable code. See MPEP § 608.01. Claim Objections Claim 132 is objected to for reciting “wherein the CCR8 biding domain” as it appears applicants meant to recite “binding” domain. Appropriate correction or clarification is requested. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 129, and 131-148 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a written description rejection. The claims are broadly drawn to a multitude of VHH anti-CCR8 antibodies. In particular, Claim 129 is drawn to a mix and match of VHH CDRs including at least 20% variability to the claimed sequences. For example, the complementary determining one region (CDR1) can be any one of SEQ ID NOs: 2, 3, 11-12, 47, 54, 57, 58, 112-119, 139-145, or 210-214 or any sequence thereto with at least 80% identity. These claims assume that one would be able to mix and match the VHH CDRs of different numbering definitions (e.g., Kabat, Chothia, IMGT) and arrive at an antibody that binds to the CCR8 antigen. However, according to Applicant’s disclosure (e.g., Table 4, page 95) there are specific SEQ ID pairings for each HCDR1-3 set (e.g., Kabat, Chothia, IMGT- See Figures 6 and 8- showing different alignments based on particular numbering schemes). One of ordinary skill in the art would understand that to mix and match HCDRs between different definitions, the HCDR1-3 sequences must be identical (e.g., variability can only occur in non-CDR regions of the VHH). Further, the claim(s) encompass CDRs comprising variability (e.g., 80% identical) which are claimed as having the function of specifically binding to CCR8. This means that the variability in sequence identity specifically occurs in the CDRs, (or could occur in the CDRs- in Claims 132, 145) the domains that are critical for the antibody binding to its target, which one of ordinary skill in the art would understand to result in unpredictable binding characteristics with no reasonable expectation of maintaining CCR8 antigen binding. Additionally, the instant disclosure does not provide a structure-function correlation that would allow for a person of ordinary skill in the art to envision what variation can occur to the VHH antibody CDR regions, such that the obtained structure would result in the claimed functions. Thus, the claims encompass a large genus of extremely diverse polypeptide variable domains that must retain functional binding to CCR8. The diversity is of high concern because the variable region of the claimed binding polypeptides comprises an extremely large genus of undefined complementary determining regions (CDRs). The written description requirement for a claimed genus may be satisfied through sufficient description of a representative number of species by actual reduction to practice, reduction to drawings, or by disclosure of relevant, identifying characteristics, i.e., structure or other physical and/or chemical properties, by functional characteristics coupled with a known or disclosed correlation between function and structure, or by a combination of such identifying characteristics, sufficient to show the applicant was in possession of the claimed genus. See Eli Lilly, 119 F.3d at 1568, 43 USPQ2d at 1406. A “representative number of species” means that the species which are adequately described are representative of the entire genus. Thus, when there is substantial variation within the genus, one must describe a sufficient variety of species to reflect the variation within the genus. However, given the substantial antibody structure variation within the genus, as well as the high level of unpredictability in the art, the claimed genus is not sufficiently representative of the entire genus. At the time of filing, VHH single domain antibody antigen binding domain functionality was known to depend on the entire structure, particularly a full complement of three CDRs. It is understood by one of ordinary skill in the art that that uncharacterized CDR binding is unpredictable and that each construct requires functional testing. Bever et al. (Anal Bioanal Chem (2016) 408:5985–6002; hereinafter “Bever”) teaches VHH antibodies, and the production and screening thereof [e.g., title, abstract]. Bever teaches Nanobodies® are VHH domain antibodies that are heavy chain only (e.g. HcAb) that are naturally produced by camelids and sharks [e.g., pg. 5985, “Introduction”]. Bever teaches the overview of process of making VHH antibodies wherein (1) an alpaca is the camelid species, (2) mRNA is collected from the alpaca and a cDNA library is constructed therefrom, (3) VHH genes are isolated, (4) a phage-display VHH library is generated, (5) solid phase panning conducted to select the desired VHH, and (6) desired VHH is obtained [e.g., fig. 2]. Hacisuleyman and Erman (Journal of Biological Physics (2020) 46:189–208; hereinafter “Hacisuleyman”) teaches VHH optimization [e.g., title, abstract]. Hacisuleyman teaches VHH antibodies comprise 3 CDRs which determine target specificity, with CDR3 being the “dominating contributor in antigen recognition” [e.g., pg. 191; fig. 2]. Hacisuleyman further teaches residue numbers for the VHH CDRs may vary, and that in nature CDRs are mutated naturally to increase the binding affinity and specificity towards a target antigen [e.g., pg. 191]. Hacisuleyman teaches that computational screening methods for optimization are a first step that is then followed by experimental strategies [e.g., pg. 191]. Hacisuleyman does not support de novo generation of VHH CDRs to bind a selected antibody, but rather requires the researcher start with a VHH antibody known to bind the target antigen [e.g., 191]. As indicated by the art above, a full complement of 3 HCDRs are required for VHH single domain antibody-antigen binding and one cannot predict all of the possible CDR sequence combinations (e.g., mix and matching of CDRs) and/or mutations to existing CDR sequence(s) that will result in a VHH single domain antibody that binds CCR8. Written description can be met if the claims recite the minimal structure that is needed to perform the function recited in the claims. Above, the art indicates that 3 defined CDRs in a VHH single domain antibody antigen-binding domain are the minimal structure that binds to a target antigen. Allowable Subject Matter Claim 130 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Any inquiry concerning this communication or earlier communications from the examiner should be directed to GARY B NICKOL, Ph.D. whose telephone number is (571)272-0835. The examiner can normally be reached M-F 9AM-5:30PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Julie Wu can be reached at 571-272-5205. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /GARY B NICKOL/Primary Examiner, Art Unit 1643
Read full office action

Prosecution Timeline

Apr 26, 2024
Application Filed
Oct 27, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12774350
ANTIBODIES BINDING TO CD3 AND FOLR1
3y 10m to grant Granted Oct 27, 2026
Patent 12760116
PROSTATE-SPECIFIC MEMBRANE ANTIGEN BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS
6y 5m to grant Granted Oct 13, 2026
Patent 12760104
ANTI-VISTA ANTIBODIES AND USES THEREOF
3y 2m to grant Granted Oct 13, 2026
Patent 12753220
New mesothelin specific chimeric antigen receptors (CAR) for solid tumors cancer immunotherapy
4y 3m to grant Granted Oct 06, 2026
Patent 12752015
ANTI-GALECTIN 3 ANTIBODIES AND THEIR USE IN EPILEPSY AND RELATED DISEASES
1y 0m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
47%
Grant Probability
77%
With Interview (+30.0%)
3y 9m (~1y 3m remaining)
Median Time to Grant
Low
PTA Risk
Based on 74 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month